Isopeptidase-Fluorogenic Assays

FXIII-Assay Kit

Based on substrate A101

1 Kit 575 € available

Art. No. F001
Assay principle Factor XIII is converted by Thrombin into Factor XIIIa. At the same time, Thrombin converts Fibrinogen into Fibrin. The clotting is prevented by an aggregation inhibiting peptide. Factor XIIIa cleaves a dark quenching molecule from the side chain of a modified peptide incorporating glycine methyl ester. Subsequently, the fluorescence of an N-terminal coupled dye increases and can be monitored on-line (excitation wavelength 313 nm; emission wavelength 418 nm). Basically, the isopeptidase activity of Factor XIIIa was described by Parameswaran et al., the modified peptide used is intellectual property of Zedira.

FXIII assay kit
Reagents in the kit (1) SUBSTRATE REAGENT: 2 x 20 μL modified peptide dissolved in DMSO
(2) ACTIVATOR REAGENT: 2 x 100 NIH Units human Thrombin, lyophilized
(3) BUFFER REAGENT: 2 x TRIS buffer pH 7.5 containing calcium chloride, sodium chloride, poly ethylene glycol (PEG), glycine methyl ester, clot inhibitor peptide, Heparin antagonist (hexadimethrine bromide) and sodium azide, lyophilized
Equipment The Fluorescent Factor XIII assay can be used in standard fluorescence spectrophotometers. Refer to the instructions of the manufacturer.
Intended use Determination of Factor XIII activity in plasma samples.
Reference(s) Oertel et al., Anal. Biochem. 2007, 367:152-8
Sossdorf et al., Crit. Care. 2009,13:R208


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA